HOOKIPA Pharma Inc.
Silvia S. has a diverse work experience spanning over several companies. Silvia is currently working at HOOKIPA Pharma Inc. as an Executive Director in Cost Accounting & Controlling, starting in May 2021. Prior to this, they worked at Gilead Sciences for over 10 years, holding various finance-related roles such as Associate Director Finance, Senior Manager FP&A, and Finance Manager FP&A. Their tenure at Gilead Sciences lasted from 2010 to 2021. Prior to that, they worked at PwC as a Manager from 2003 to 2010.
Silvia S. attended WU (Vienna University of Economics and Business) but the specific details of their degree, field of study, and the duration of their education are not provided.
This person is not in any offices
HOOKIPA Pharma Inc.
At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.